2
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
71
Observational
2
Expanded_access
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
1
Interventions
3-Iodobenzylguanidine
9
Amifampridine
6
nilotinib
5
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
trametinib
4
pembrolizumab
4
gallium 68 PSMA-11
4
fludarabine
4
elotuzumab
4
dabrafenib
4
Nivolumab
4
Bortezomib
4
Afatinib
4
venetoclax
3
regorafenib
3
midostaurin
3
fludarabine phosphate
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Lenalidomide
3
Ipilimumab
3
Everolimus
3
Dexamethasone
3
Crizotinib
3
Capecitabine
3
Axitinib
3
Alpelisib
3
Abiraterone Acetate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
surufatinib
×
Clear all
NCT04814732
2024-04-12
Expanded Access Program of Surufatinib
Hutchmed
No longer available